SpringWorks TherapeuticsSWTX
SWTX
0
Funds holding %
of 7,390 funds
0
Analysts bullish %
of 4 analysts
Fund manager confidence
Based on 2024 Q4 regulatory filings by fund managers ($100M+ AUM)
75% more funds holding in top 10
Funds holding in top 10: 4 [Q3] → 7 (+3) [Q4]
42% more repeat investments, than reductions
Existing positions increased: 88 | Existing positions reduced: 62
13% more capital invested
Capital invested by funds: $2.59B [Q3] → $2.92B (+$330M) [Q4]
0.18% less ownership
Funds ownership: 108.9% [Q3] → 108.72% (-0.18%) [Q4]
10% less first-time investments, than exits
New positions opened: 38 | Existing positions closed: 42
4% less funds holding
Funds holding: 223 [Q3] → 215 (-8) [Q4]
17% less call options, than puts
Call options by funds: $10.4M | Put options by funds: $12.6M
Research analyst outlook
4 Wall Street Analysts provided 1 year price targets over the past 3 months
Low target
$65
37%
upside
Avg. target
$74
55%
upside
High target
$78
65%
upside
4 analyst ratings
4 positive
100%
0 neutral
0%
0 negative
0%
HC Wainwright & Co. Robert Burns 20% 1-year accuracy 33 / 167 met price target | 56%upside $74 | Buy Reiterated | 24 Feb 2025 |
Wedbush David Nierengarten 35% 1-year accuracy 42 / 119 met price target | 62%upside $77 | Outperform Reiterated | 12 Feb 2025 |
Evercore ISI Group Cory Kasimov 44% 1-year accuracy 7 / 16 met price target | 37%upside $65 | Outperform Maintained | 12 Feb 2025 |
Guggenheim Michael Schmidt 32% 1-year accuracy 11 / 34 met price target | 65%upside $78 | Buy Maintained | 8 Jan 2025 |
Financial journalist opinion
Based on 3 articles about SWTX published over the past 30 days
Neutral
Market Watch
3 days ago
Biotech stocks have been hit hard. Why they're a great value now.
Biotech is one of the U.S. stock market's most unloved sectors. But several indicators suggest that a bottom in sentiment could be near, and that's normally a good time to buy.
Positive
Zacks Investment Research
2 weeks ago
SpringWorks Shares Rise More Than 30% in 3 Months: Here's Why
SWTX's desmoid tumor drug, Ogsiveo, is driving its top line. The recent FDA nod for Gomekli to treat a rare tumor diversifies its commercial portfolio.
Positive
Seeking Alpha
2 weeks ago
SpringWorks Therapeutics: Promising Launches, Expanding Pipeline, And M&A Buzz
SpringWorks Therapeutics portfolio features Ogsiveo for desmoid tumors and Gomekli for NF1‑plexiform neurofibromas. In fact, Ogsiveo's revenues alone reached $172 million in 2024, supported by orphan drug designations in the US and EU. Similarly, Gomekli is the first FDA-approved MEK inhibitor for NF1‑plexiform neurofibromas, which targets both adults and children.
Positive
Zacks Investment Research
1 month ago
SpringWorks' Q4 Loss Wider Than Expected, Revenues Beat Estimates
SWTX reports mixed fourth-quarter 2024 results. Its newly approved desmoid tumor drug, Ogsiveo, witnesses a strong launch.
Negative
Benzinga
1 month ago
Top 3 Health Care Stocks You May Want To Dump In February
As of Feb. 20, 2025, three stocks in the health care sector could be flashing a real warning to investors who value momentum as a key criteria in their trading decisions.
Negative
Zacks Investment Research
1 month ago
SpringWorks Therapeutics (SWTX) Reports Q4 Loss, Tops Revenue Estimates
SpringWorks Therapeutics (SWTX) came out with a quarterly loss of $1.04 per share versus the Zacks Consensus Estimate of a loss of $0.72. This compares to loss of $1.44 per share a year ago.
Neutral
GlobeNewsWire
1 month ago
SpringWorks Therapeutics Reports Fourth Quarter and Full Year 2024 Financial Results and Highlights Recent Business Updates
– Achieved $61.5 million and $172.0 million in fourth quarter and full year 2024 OGSIVEO ® (nirogacestat) U.S. net product revenues, respectively –
Neutral
PRNewsWire
1 month ago
SpringWorks Therapeutics and Jewelry Designer Jennifer Fisher Team Up to Encourage People with Desmoid Tumors to Take Action Before Their Tumor Takes Over
- Educational campaign aims to raise awareness and drive conversation about desmoid tumors, the devastating impact they have on patients' lives - STAMFORD, Conn. , Feb. 19, 2025 /PRNewswire/ -- SpringWorks Therapeutics, Inc. (Nasdaq: SWTX), a commercial-stage biopharmaceutical company focused on severe rare diseases and cancer, and Jennifer Fisher, jewelry designer and desmoid tumor patient advocate, are collaborating to increase understanding of desmoid tumors as well as to encourage patients to find a specialist, like an oncologist with experience treating desmoid tumors who can discuss available treatment options to manage their desmoid tumor.
Neutral
GlobeNewsWire
1 month ago
Onco360 Has Been Selected as a National Specialty Pharmacy Partner for GOMEKLI™ (mirdametinib), Manufactured By SpringWorks Therapeutics
LOUISVILLE, Ky., Feb. 17, 2025 (GLOBE NEWSWIRE) -- Onco360®, the nation's leading independent specialty pharmacy, has been selected as a national pharmacy partner by SpringWorks Therapeutics, Inc. for GOMEKLI (mirdametinib). The Food & Drug Administration approved GOMEKLI for the treatment of adult and pediatric patients 2 years of age and older with neurofibromatosis type 1 (NF1) who have symptomatic plexiform neurofibromas (PN) not amenable to complete resection.1
Negative
Zacks Investment Research
1 month ago
SpringWorks Therapeutics (SWTX) May Report Negative Earnings: Know the Trend Ahead of Next Week's Release
SpringWorks Therapeutics (SWTX) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Charts implemented using Lightweight Charts™